BioAtla, Inc. (BCAB)
$1.25-16.67%Close
SELLCRISIS · day 33
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $2M
- Beta
- 0.76
- P/E (TTM)
- -0.07
- Short % float
- 7.06%
- Days to cover
- 1.4
- SI change
- -19.7%
- 1W
- -5.30%
- 1M
- -16.67%
- vs SPY 1W
- -5.16%
- vs SPY 1M
- -19.17%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 1
- VALUE
- 6
- GROWTH
- 35
- GARP
- 2
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC53.5%
REV YoY-
ROE89.2%
EPS YoY-
ROA-330.9%
GROSS100
OP-378
NET-370
[VALUATION]
P/E TTM-0.07
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B-0.08
P/FCF-
EV/EBITDA-0.23
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO0.20
ND/EBITDA-
BETA0.76
Company news
Loading headlines…
FAQ
- What is LOPJLB’s current signal on BCAB?
- LOPJLB’s latest quantitative signal on BioAtla, Inc. (BCAB) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is BCAB in?
- BioAtla, Inc. (BCAB) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does BioAtla, Inc. (BCAB) do?
- BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sa…